Bortezomib will enhance the level or influence of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Increased flibanserin adverse results may perhaps happen if coadministered with many weak CYP3A4 inhibitors. To cut back the potential risk of dizziness and lightheadedness, rise up gradually when mounting from the sitting or https://christopherw822pqx5.blog5star.com/profile